Skip to Content


Treatment for Obesity

Rimonabant USA: Update - Feb 12, 2007

PARIS, February 12 2007 -- Sanofi-aventis announced today that the review period of rimonabant in the United State has been extended by three months, until July 27, 2007.

The Group also announced the submission of the SERENADE clinical study report today in the rimonabant NDA submitted to the FDA.

Rimonabant is a first- in-class cannabinoid type 1 receptor discovered and developed by sanofi- aventis.

SERENADE (Study Evaluating Rimonabant Efficacy in Drug-NAive DiabEtic Patients) is a multi-centre, randomized, double-blind, placebo-controlled, parallel-group study comparing rimonabant 20 mg once daily to placebo in improving blood sugar control in treatment-naive type 2 diabetic patients not adequately controlled by diet alone for a period of six months.

Source: sanofi-aventis

Posted: February 2007

Related Articles

Zimulti (rimonabant) FDA Approval History